X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (58) 58
humans (57) 57
bortezomib (54) 54
male (43) 43
aged (42) 42
middle aged (41) 41
female (40) 40
multiple myeloma - drug therapy (40) 40
hematology (36) 36
boronic acids - administration & dosage (32) 32
pyrazines - administration & dosage (32) 32
adult (31) 31
aged, 80 and over (26) 26
treatment outcome (26) 26
multiple myeloma (25) 25
antineoplastic combined chemotherapy protocols - therapeutic use (22) 22
boronic acids - adverse effects (22) 22
pyrazines - adverse effects (22) 22
oncology (21) 21
recurrence (21) 21
abridged index medicus (18) 18
antineoplastic combined chemotherapy protocols - adverse effects (18) 18
dexamethasone (18) 18
stem-cell transplantation (18) 18
antineoplastic agents - therapeutic use (16) 16
boronic acids - therapeutic use (14) 14
dexamethasone - administration & dosage (14) 14
disease-free survival (14) 14
multiple myeloma - mortality (14) 14
pyrazines - therapeutic use (14) 14
thalidomide (14) 14
therapy (14) 14
antineoplastic agents - administration & dosage (12) 12
follow-up studies (12) 12
multiple myeloma - pathology (12) 12
analysis (11) 11
antineoplastic agents - adverse effects (11) 11
multiple-myeloma (11) 11
prednisone - administration & dosage (11) 11
care and treatment (10) 10
combination (10) 10
drug administration schedule (10) 10
hemic and lymphatic diseases (10) 10
melphalan - administration & dosage (10) 10
prednisone (10) 10
refractory myeloma (9) 9
thalidomide - administration & dosage (9) 9
antineoplastic combined chemotherapy protocols - administration & dosage (8) 8
dose-response relationship, drug (8) 8
kaplan-meier estimate (8) 8
peripheral neuropathy (8) 8
thalidomide - analogs & derivatives (8) 8
chemotherapy (7) 7
clinical trials (7) 7
dexamethasone - adverse effects (7) 7
drug resistance, neoplasm (7) 7
immune system diseases (7) 7
lenalidomide (7) 7
melphalan (7) 7
neoplasm staging (7) 7
pharmacokinetics (7) 7
survival (7) 7
survival analysis (7) 7
trial (7) 7
cancer (6) 6
cells (6) 6
clinical trials and observations (6) 6
corticosteroids (6) 6
cyclophosphamide (6) 6
dexamethasone - therapeutic use (6) 6
doxorubicin - administration & dosage (6) 6
multiple myeloma - genetics (6) 6
plus dexamethasone (6) 6
prognosis (6) 6
protease inhibitors - administration & dosage (6) 6
protease inhibitors - therapeutic use (6) 6
research (6) 6
safety (6) 6
antibodies, monoclonal, murine-derived - administration & dosage (5) 5
antineoplastic agents - pharmacokinetics (5) 5
apoptosis (5) 5
doxorubicin - adverse effects (5) 5
drug therapy (5) 5
glycine - analogs & derivatives (5) 5
induction (5) 5
medical colleges (5) 5
medical research (5) 5
medicine, experimental (5) 5
multiple myeloma - blood (5) 5
patients (5) 5
peripheral nervous system diseases - chemically induced (5) 5
product development (5) 5
protease inhibitors - adverse effects (5) 5
proteasome inhibitor (5) 5
rituximab (5) 5
survival rate (5) 5
thalidomide - adverse effects (5) 5
apex trial (4) 4
boron compounds - administration & dosage (4) 4
bortezomib - administration & dosage (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 5, pp. 431 - 440
Journal Article
Blood, ISSN 0006-4971, 08/2010, Volume 116, Issue 5, pp. 679 - 686
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 05/2015, Volume 79, Issue 5, pp. 789 - 800
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2016, Volume 374, Issue 17, pp. 1621 - 1634
The addition of the oral proteasome inhibitor ixazomib to a regimen of lenalidomide plus dexamethasone led to a significant prolongation of progression-free... 
SUPERIORITY | MEDICINE, GENERAL & INTERNAL | CARFILZOMIB | RANDOMIZED PHASE-3 | THERAPY | PROTEASOME INHIBITOR MLN9708 | QUALITY-OF-LIFE | BORTEZOMIB | THALIDOMIDE | ANTITUMOR-ACTIVITY | TRANSPLANTATION | Glycine - analogs & derivatives | Glycine - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Boron Compounds - administration & dosage | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Exanthema - chemically induced | Aged, 80 and over | Adult | Glycine - administration & dosage | Dexamethasone - administration & dosage | Double-Blind Method | Administration, Oral | Kaplan-Meier Estimate | Proportional Hazards Models | Thrombocytopenia - chemically induced | Thalidomide - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quality of Life | Boron Compounds - adverse effects | Aged | Care and treatment | Dosage and administration | Dexamethasone | Multiple myeloma | Thrombocytopenia | Inhibitor drugs | Risk groups | Drug therapy | Peripheral neuropathy | Survival | Patients | Drug dosages | Proteasome inhibitors | Quality of life | Index Medicus | Abridged Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2013, Volume 31, Issue 26, pp. 3279 - 3287
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2015, Volume 33, Issue 33, pp. 3921 - 3929
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2013, Volume 31, Issue 4, pp. 448 - 455
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2017, Volume 35, Issue 31, pp. 3538 - 3546
Journal Article
Journal Article
Blood, ISSN 0006-4971, 03/2014, Volume 123, Issue 10, pp. 1461 - 1469
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2005, Volume 352, Issue 24, pp. 2487 - 2498
Journal Article